...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Participation at the ACC/WCC Virtual Meeting

Thanks Bear. Two very interesting and exciting posters. What diappoints me is that the CHF study is not on the program as an oral presentation, a little odd when the data are so impressive (zero hospitalizations on apabetalone after 24 months of treatment). Perhaps it's because of the prior presentation of some of the data at the AHA.

 

Share
New Message
Please login to post a reply